Repatha

#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Peter Attia MD

Another brand name for a PCSK9 inhibitor, also mentioned for its variable effect on Lp(a) reduction.

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

Peter Attia MD

A PCSK9 inhibitor developed by Amgen that demonstrated significant event reduction in the FOURIER trial, even in high-risk patients with already low LDL-C on statins.

Peter Diamandis and Tony Robbins on strategies that promote longevity now – and in the near future

FoundMyFitness

A monoclonal antibody treatment for hypercholesterolemia that lowers LDL levels by blocking PCSK9.

276 ‒ Special episode: Peter on longevity, supplements, protein, fasting, apoB, statins, & more

Peter Attia MD

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

A PCSK9 inhibitor drug approved by the FDA based on its LDL-lowering effects.